Report Highlights
The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.
Report Includes
- An overview of the global market for diagnostics and therapies for ovarian cancer, the fifth most common cancer in American women and the fourth most common cause of female cancer deaths.
- Country specific data and analysis for United States, Canada, Germany, United Kingdom, France, Italy, Spain, India, China, Japan, and Mexico.
- A breakdown of the markets by diagnostics and test, surgery, radiation therapy, and drug therapy.
- Discussion of ovarian cancer biology.
- Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
- Evaluation of the patent landscape.
- Comprehensive profiles of major players in the market, including Roche Holding AG, Novartis AG, Celgene Corp., and Pfizer, Inc.
Report Scope
This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.
The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.
The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Renewable Energy: Technologies and Global Markets (EGY049F)
- Wood-Plastic Composites: Technologies and Global Markets (PLS034D)
- Cancer Immunotherapy: Technologies and Global Markets (PHM129C)
- Nanotechnology in Cancer Treatment: Technologies and Global Markets (PHM222B)
- Disposable Ostomy Bags: Global Market (MDS108A)
Report Highlights
The global ovarian cancer drug and diagnostic market was valued at $16.1 billion in 2012. The market is predicted to grow to $18.7 billion in 2013 and $34.6 billion by 2018, a compound annual growth rate (CAGR) of 13.1% between 2013 and 2018.
Report Includes
- An overview of the global market for diagnostics and therapies for ovarian cancer, the fifth most common cancer in American women and the fourth most common cause of female cancer deaths.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- A breakdown of the markets by diagnostics and test, surgery, radiation therapy, and drug therapy.
- Discussion of ovarian cancer biology.
- Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
- Evaluation of the patent landscape.
- Comprehensive profiles of key companies.
Related Reports
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Therapeutics for Women's Health: Technologies and Global Markets
The global therapeutics for women’s health technologies market is expected to grow from $61.5 billion in 2024 and is projected to reach $81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.
Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
Recent Reports
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Clinical Trial Infrastructure Regional Analysis Market: Middle East and North Africa
This report provides an overview of the clinical trial infrastructure markets in the Middle East and North Africa (MENA) region. It includes a detailed examination of the market dynamics and an understanding of the MENA clinical trial landscape by study status, phase, type, results and sponsor type.
Intravenous (IV) Therapy and Vein Access: Global Markets
The global market for IV therapy and venous access devices is expected to grow from $57.0 billion in 2024 and is projected to reach $74.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.5% during the forecast period of 2024 to 2029.
Global Colorectal Cancer Screening and Diagnostics Market
The global market for colorectal cancer screening and diagnostic testing services is estimated to increase from $40.0 billion in 2024 to reach $46.1 billion by 2029, at a compound annual growth rate (CAGR) of 2.9% from 2024 through 2029.
Medical Imaging: A BCC Research Outlook
The global market for medical imaging is expected to grow from $63.4 billion in 2024 and is projected to reach $82.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.5% during the forecast period of 2024 to 2029.
Top Trending Reports
Global Diabetic Care Devices Market
The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.
Carbon Capture, Utilization & Storage Technologies
The global market for carbon capture, utilization and storage (CCUS) technologies is expected to grow from $3.4 billion in 2024 and is projected to reach $9.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.1% during the forecast period of 2024 to 2029.
2024 Semiconductor Manufacturing Research Review
This 2024 Research Review of the Semiconductor Manufacturing provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions.
2024 Medical Devices Research Review
The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.
Generative AI: Global Markets
The global market for generative AI was valued at $15.4 billion in 2023. It is projected to grow from $20.8 billion in 2024 to $94.4 billion by 2029, at a compound annual growth rate (CAGR) of 35.3% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More